ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT Goodwill

The premium paid for acquisitions above the fair value of the identifiable net assets acquired.

ClearPoint Neuro, Inc.NASDAQ: CLPT

Goodwill · Q1 FY2026 · quarter ended Mar 2026

Goodwill remains negative

Q1 FY2026 goodwill was $7.47M, compared with $0 a year earlier.

Context

  • Goodwill amounted to 8.0% of total assets at the end of Q1 FY2026, up 8.0 pp from a year earlier.
  • Goodwill increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.47M+0.0% QoQ
Last fiscal yearDec 2025
$7.47M— YoY
Year agoMar 2025
$0— since
Goodwill past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Goodwill history

USD · from the balance sheet

Latest · FY2025
7.47M USD
Year-over-year change
—

Goodwill vs competitors

How CLPT compares with its peers on the latest reported figures

  • Peers report in different currencies, so goodwill is compared through growth and share of total assets rather than absolute size.
  • Goodwill amounts to 8.0% of total assets for CLPT, versus a peer median of 9.7%.
CLPT Competitors
Goodwill for CLPT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AVNSAvanos Medical, Inc.Mar 2026$394M USD-13.6%-19.6%37.5%
VREXVarex Imaging CorporationApr 2026$197.8M USD-31.9%-11.3%18.2%
OFIXOrthofix Medical Inc.Mar 2026$194.93M USD+0.0%+39.8%22.0%
SNDLSNDL Inc.Mar 2026CA$127.17M CAD+2.4%+22.7%9.7%
AKBAAkebia Therapeutics, Inc.Mar 2026$59.04M USD+0.0%+0.0%16.3%
CTKBCytek Biosciences, Inc.Mar 2026$16.69M USD+0.1%+18.1%3.7%
CLPTClearPoint Neuro, Inc.Mar 2026$7.47M USD——8.0%
CMPSCOMPASS Pathways plcMar 2026$0 USD——0.0%
SIBNSI-BONE, Inc.Mar 2026$0 USD——0.0%
LABStandard BioTools Inc.Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding CLPT) —+0.0%+9.0%9.7%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents54.11M27.62M23.14M20.1M45.92M
Short-term Investments09.87M000
Net Receivables2.34M2.67M3.94M4.71M7.26M
Inventory4.94M9.3M7.91M6.86M8.36M
Other Current Assets01.72M01.68M2.06M
Total Current Assets61.89M51.18M36.17M33.36M63.6M
Property, Plant & Equipment (Net)2.78M2.7M4.95M5.09M11.05M
Goodwill00007.47M
Intangible Assets265K1.03M1.04M484K13.92M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets644K581K495K251K1.7M
Total Non-current Assets3.69M4.31M6.49M5.83M34.15M
Total Assets65.58M55.49M42.66M39.19M97.75M
Account Payables427K272K393K1.34M1.26M
Short-term Debt00000
Tax Payables00000
Deferred Revenue678K1.07M2.61M2.12M1.67M
Other Current Liabilities2.6M2.82M2.95M4.89M4.36M
Total Current Liabilities4.75M6.79M7.43M10.35M10.77M
Long-term Debt9.84M9.89M9.95M049.08M
Deferred Tax Liabilities0000354K
Deferred Revenue (Non-current)264K390K541K436K581K
Other Non-current Liabilities0000489K
Total Non-current Liabilities12.04M11.82M14.06M3.45M58.96M
Total Liabilities16.79M18.6M21.49M13.8M69.73M
Common Stock237K246K247K276K294K
Retained Earnings(133.93M)(150.37M)(172.46M)(191.37M)(216.91M)
Accumulated OCI00005.64M
Other Stockholders Equity00000
Minority Interest00000
Total Equity48.79M36.89M21.17M25.39M28.02M
Total Debt12.28M11.99M13.94M3.57M58.23M
Net Debt(41.83M)(15.63M)(9.2M)(16.54M)12.31M

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.